Massive drug companies, early-stage startups and a wide range of intellectual property groups were among many parties Tuesday urging the U.S. Supreme Court to hold that the Federal Circuit erred when invalidating Amgen patents in a fight over how to interpret when a patent meets enablement requirements.
- Sat. Jun 3rd, 2023
